| Name | Title | Contact Details |
|---|
Tottenham Hotspur is a world-famous football club based in London. On the pitch, the Club competes in the upper echelons of the English Premier League and is a regular participant in marque UEFA club competitions. Off the pitch, the Club has a strong and successful business model centered around building a platform for long-term success, which includes a world-class training centre and now a brand new 62,214 seater world-class stadium. The Club operates out of multiple sites, including its Headquarters at Lilywhite House adjacent to the Tottenham Hotspur Stadium, the Training Centre, our state-of-the-art training facilities in Enfield or the Warehouse, the home of our Retail and Merchandise division in Brimsdown Were so proud of our rich history. From humble beginnings in North London, we became the first and, to date, only non-league side to win the FA Cup in 1901 – the first of eight triumphs in the age-old, world-renowned competition thus far.
BMW of Buena Park is one of the largest and most popular BMW dealerships in the Buena Park area. Our dealership features an extensive inventory of new and pre-owned BMW vehicles for sale, exclusive BMW lease specials and financing offers, a state-of-the-art service center, and an experienced team of BMW enthusiasts ready to assist you with any request you may have.
Intact Public Entities is a leader in providing specialized insurance programs, including risk management and claims services to municipal, public administration and community service organizations across Canada. Proven industry knowledge, gained through over nine decades of partnering with insurance companies and independent brokers, gives Intact Public Entities the ability to effectively manage the necessary risk, advisory and claims services for both standard and complex issues. Our history dates back to 1927 with our first municipal client - the Village of Ayr, Ontario. From then, other municipalities came calling and the company established the strong foundation and sterling reputation that continues today. Interestingly, our product offering was expanded beyond municipal business based on reputation. Other municipal-related organizations started to be asked to be placed with us because of our knowledge in the specialty insurance space. The trend continued and it became common for the municipality, hospital, Childrens Aid Society and conservation authority to all be placed wtih Intact Public Entities. Intact Public Entities is a Managing General Agent (MGA) with the authority to write and service business on behalf of strategic partners who share our commitment and dedication to protecting specialized organizations. Because our partners are long-term participants on our program, they understand the nature of fluctuating market conditions and complex claims and are prepared to stay the course. Intact Public Entities is a wholly owned subsidiary of Intact Financial Corporation.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.